QV Bioelectronics Company
QV Bioelectronics is striving to deliver longer, better quality lives to brain tumour patients through their first of its kind electric field therapy implant, GRACE. GRACE has been designed alongside some of the leading neurosurgeons in the UK, with the aim of extending patient life expectancy without impacting patient quality of life. For patients with the most common primary brain tumour, glioblastoma, there has been a severe lack of new, effective treatments for decades, with only a handful of approved options. Because of this, glioblastoma has some of the worst outcomes of any cancer, with a 5-year survival rate of <5. Co-founder and academic neurosurgeon Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for patients but also by major design flaws in newer electric field therapy approaches. Working together with Dr Chris Bullock, a biomedical engineer who had been carrying out research at Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. QV Bioelectronics was founded to their solution GRACE, to patients. Since then, their ground-breaking materials science research has received nearly $1M in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK, as well as over $1M in equity funding from international life science seed investors SOSV, and renowned life-science investors in Consilience & Catapult Ventures. QV now have an expert, multidisciplinary team with decades of experience working bringing GRACE to the clinic from their research hub in Alderley Park, Cheshire.
